Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06815471 · ClinicalTrials.gov registry record · Phase 2
CRF2 Agonist for the Treatment of Worsening Heart Failure
A Phase 2 study of Worsening Heart Failure, sponsored by Corteria Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT06815471: Recruiting Phase 2 study of Worsening Heart Failure, sponsored by Corteria Pharmaceuticals.
NCT06815471 is a Phase 2 study of Worsening Heart Failure that is actively recruiting participants, run by Corteria Pharmaceuticals. The registered enrollment target is 300 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06815471, a Phase 2 study of Worsening Heart Failure, is actively recruiting participants, sponsored by Corteria Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG COR-1167
Study Locations (20)
Other
- Sdružené zdravotnické zařízení Krnov - Krnov
- Nemocnice Slaný - Slaný
- Aleksandre Aladashvili Clinic LLC - Tbilisi
- LTD "Israeli-Georgian Medical Research Clinic Healthycore" - Tbilisi
- Acad. G. Chapidze Emergency Cardiology Center LTD, Department of Internal Medicine and Medical Research - Tbilisi
- Acad. G.Chapidze Emergency Cardiology Center, LTD, Department of Multi-center Clinical Trials - Tbilisi
- Bokhua Memorial Cardiovascular Center LTD - Tbilisi
- St. Michael's Hospital LLC - Tbilisi
- Tbilisi Heart and Vascular Clinic, LTD - Tbilisi
- Georgian Dutch Hospital - Tbilisi
- LTD Tbilisi Heart Center - Tbilisi
- Semmelweis Egyetem, Általános Orvostudományi Kar, Városmajori Szív- és Érgyógyászati Klinika - Budapest
- Budapesti Uzsoki Utcai Kórház, Kardiológia Osztály - Budapest
- Pécsi Tudományegyetem, Klinikai Központ, I. sz. Belgyógyászati Klinika - Pécs
North Carolina
- Cone Health Moses Cone Hospital - Greensboro
- NC Heart and Vascular Research, LLC - Raleigh
Indiana
- Indiana University Health Methodist Hospital - Indianapolis
Ohio
- Ohio State University - Columbus
Oklahoma
- South Oklahoma Heart Research, LLC - Oklahoma City
Czech Republic
- Fakultní nemocnice Ostrava - Ostrava
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-08-07 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT06815471 shows while recruiting
NCT06815471 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher).
The record links to 1 condition, with Worsening Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06815471 names 20 study sites across 6 states, led by Other, North Carolina, Indiana.
Frequently Asked Questions
What is clinical trial NCT06815471 about?
NCT06815471 is a clinical study titled "CRF2 Agonist for the Treatment of Worsening Heart Failure". This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)
What is the current status of trial NCT06815471?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2025-08-07. Estimated completion is 2026-12.
What conditions does trial NCT06815471 study?
This clinical trial studies the following conditions: Worsening Heart Failure.
What interventions are being tested in trial NCT06815471?
The interventions under investigation include: Placebo (DRUG), COR-1167 (DRUG).
Who is sponsoring clinical trial NCT06815471?
This trial is sponsored by Corteria Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06815471 being conducted?
This trial has 20 study locations across Indiana, North Carolina, Ohio, Oklahoma, Czech Republic. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06815471's enrollment target sits among peer trials
300 167th of 2000 higher than 1,814 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI